Gildeuretinol Acetate versus Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration
Ophthalmology Retina · 2026-10 · 10 (10) · 1027-1035
DOI: 10.1016/j.oret.2026.05.018 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Ophthalmology Retina, 2026-10. Verfasst von David S Boyer und 12 weiteren Autor:innen. Beteiligte Einrichtung: Retina Vitreous Associates Medical Group, Los Angeles, California. Electronic address: vitdoc@aol.com. Hauptthemen laut MEDLINE: Visual Acuity, Geographic Atrophy, Macular Degeneration. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NEI NIH HHS, NEI.
Abstract (Originalsprache)
OBJECTIVE: To assess the effects of gildeuretinol acetate (C20D3-vitamin A) in geographic atrophy (GA). DESIGN: A 24-month, double-masked, multicenter, randomized, placebo-controlled trial. PARTICIPANTS: Participants aged ≥60 years with GA. INTERVENTIONS: Randomized 2:1 to oral gildeuretinol acetate 14 mg daily or placebo. MAIN OUTCOME MEASURES: The primary endpoint was GA growth rate from baseline to 24 months. A prespecified sensitivity analysis accounted for a 6-month delay in onset of therapeutic effect. Secondary endpoints included change from baseline in low-luminance visual acuity (LLVA), best-corrected visual acuity (BCVA), Visual Function Questionnaire-25, and Functional Reading Independence (FRI) Index. RESULTS: Among 198 randomized participants (mean [standard deviation {SD}] age, 78.4 [7.0] years; 68.7% women), 69.2% completed the 24-month study. In the gildeuretinol and placebo groups, baseline mean (SD) total GA lesion area in mm2 was 7.72 (6.10) and 7.09 (4.16); BCVA letter scores were 56.2 (21.3) (Snellen equivalent: ∼20/80) and 58.8 (18.0) (∼20/70); and LLVA letter scores were 31.1 (19.0) (∼20/200) and 31.6 (17.8) (∼20/250), respectively. Mean GA growth rates were 1.62 mm2/yr with gildeuretinol and 1.87 mm2/yr with placebo (least squares [LSs] mean difference: -0.25 mm2/yr; 95% confidence interval [CI]: -0.53 to 0.03; P = 0.075), a 13.4% relative reduction for gildeuretinol versus placebo. The LS mean (standard error) GA growth rates from 6 to 24 months were 1.90 (0.12) mm2/yr (placebo) and 1.61 (0.08) mm2/yr (gildeuretinol), a 15.3% relative reduction (-0.29 mm2/yr; 95% CI: -0.576 to -0.004; nominal P = 0.047). At 24 months, LLVA declined 3.9 and 8.3 ETDRS letters in the gildeuretinol and placebo groups, respectively (difference: 4.4 letters; 95% CI: 0.40-8.41; nominal P = 0.031). Best-corrected visual acuity declined 6.9 letters with gildeuretinol and 10.2 letters with placebo (difference: 3.3 letters; 95% CI: -0.63 to 7.23; P = 0.099). Visual Function Questionnaire-25 scores declined 4.81 fewer points with gildeuretinol than placebo (95% CI: 0.87-8.76; nominal P = 0.017), and FRI scores declined 0.35 fewer points (95% CI: 0.11-0.58; nominal P = 0.004). CONCLUSIONS: The prespecified primary endpoint was not met. Prespecified piecewise and secondary functional and patient-reported analyses favored gildeuretinol with nominal P values; these exploratory findings support further evaluation in adequately powered trials. TRIAL REGISTRATION: NCT03845582. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Retina Vitreous Associates Medical Group, Los Angeles, California. Electronic address: vitdoc@aol.com.
- Alkeus Pharmaceuticals, Inc, Cambridge, Massachusetts.
- Retina Group of Washington, Fairfax, Virginia.
- Vitreoretinal Consultants of New York, Great Neck, New York.
- Pacific Northwest Retina, Silverdale, Washington.
- Houston Eye Associates, Houston, Texas.
Förderung
- NEI NIH HHS
- NEI
Zitieren
APA
Boyer, D. S., Saad, L., Washington, I., Melamud, A., Graham, K. B., O'Malley, A. E., DeBartolomeo, G. M., Jiang, H., Harris, L. D., Kay, C. N., Ferrone, P. J., Khan, S., & SAGA Study Team (2026). Gildeuretinol Acetate versus Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration. Ophthalmology Retina, 10(10), 1027-1035. https://doi.org/10.1016/j.oret.2026.05.018
Vancouver
Boyer DS, Saad L, Washington I, Melamud A, Graham KB, O'Malley AE, et al. Gildeuretinol Acetate versus Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration. Ophthalmology Retina. 2026;10(10):1027-1035. doi:10.1016/j.oret.2026.05.018
BibTeX
@article{Boyer2026,
author = {Boyer, David S and Saad, Leonide and Washington, Ilyas and Melamud, Alexander and Graham, Kenneth B and O'Malley, Adrian E and DeBartolomeo, Gabrielle M and Jiang, Honghua and Harris, Lindsey D and Kay, Christine N and Ferrone, Philip J and Khan, Seemi and SAGA Study Team, SAGA Study Team},
title = {Gildeuretinol Acetate versus Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration},
journal = {Ophthalmology Retina},
year = {2026},
volume = {10},
number = {10},
pages = {1027--1035},
doi = {10.1016/j.oret.2026.05.018}
}
EUVIMED